The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies - Full Text View

Purpose

The muscular dystrophies (MD) are a group of more than 30 neuromuscular disorders that are characterized by progressive skeletal muscle weakness, defects in muscle proteins and the death of muscle cells and tissue. This study will investigate the use of far infrared radiation for managing muscular dystrophies.

Condition	Intervention	Phase
Muscular Dystrophies	Radiation: Far Infrared Radiation	Phase I

Genetics Home Reference related topics:

Duchenne and Becker muscular dystrophy Laing distal myopathy myotonic dystrophy

MedlinePlus related topics:

Muscle Disorders Muscular Dystrophy

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies.

Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:

Management and Cure of muscular dystrophies [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Rehabilitation of people with muscular dystrophies [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Estimated Enrollment:	10
Study Start Date:	May 2008
Estimated Study Completion Date:	June 2010
Estimated Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Radiation: Far Infrared Radiation (5μm to 20μm wavelength)	Radiation: Far Infrared Radiation Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.

Detailed Description:

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly cure these neuromuscular disorders.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Persons with muscular dystrophies

Exclusion Criteria:

None

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00674843

Locations


Canada, Ontario
	The Centre for Incurable Diseases
	Toronto, Ontario, Canada, M4V 1L5

Sponsors and Collaborators

GAAD Medical Research Institute Inc.

Investigators


Principal Investigator:	Sam Francis, M.D.	GAAD Medical Research Institute Inc.

More Information

Responsible Party:	GAAD Medical Research Institute Inc. ( Dr. Kwasi Donyina/Founder and President )
Study ID Numbers:	GAAD-MD-CTP1
First Received:	May 6, 2008
Last Updated:	October 7, 2008
ClinicalTrials.gov Identifier:	NCT00674843
Health Authority:	Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:

MYOTONIC DYSTROPHY

MYOPATHIES

Distal Myopathies

Muscular Dystrophy, Duchenne

Phosphorylase Deficiency (McArdle Disease)

Study placed in the following topic categories:

Dystrophia myotonica 1

Myotonia atrophica

Muscular Dystrophies

Muscular Diseases

Muscular Disorders, Atrophic

Musculoskeletal Diseases

Neuromuscular Diseases

Genetic Diseases, Inborn

Muscular Dystrophy, Duchenne

Myotonic Dystrophy

Duchenne muscular dystrophy

Atrophy

Muscular dystrophy

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on October 23, 2008

Sponsored by:	GAAD Medical Research Institute Inc.
Information provided by:	GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:	NCT00674843